Make drug companies pay the cost of a more active Food & Drug Administration, the Office of Management & Budget is telling the FDA. The OMB has advised Commissioner David Kessler that long-standing congressional opposition to FDA user fees is beginning to weaken. The budget office is counting on fees, mainly from pharmaceutical makers seeking approval for new drugs, to provide the FDA with nearly $200 million of the $770 million the agency says it needs to fund everything from a reorganized generic drug office to more aggressive regulation of food health claims.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.